Healthcare Sector
Market Tracker
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 07/02/2026 | PUT | $660.00 | 1,539 | +1,235 | +406.25% |
| 07/02/2026 | PUT | $570.00 | 906 | +667 | +279.08% |
| 07/02/2026 | PUT | $630.00 | 673 | +395 | +142.09% |
| 07/17/2026 | CALL | $1,200.00 | 3,306 | +301 | +10.02% |
| 07/17/2026 | CALL | $1,150.00 | 554 | +242 | +77.56% |
| 06/18/2026 | CALL | $1,115.00 | 261 | +235 | +903.85% |
| 06/18/2026 | PUT | $980.00 | 367 | -53 | -12.62% |
| 06/18/2026 | CALL | $1,250.00 | 485 | -61 | -11.17% |
| 06/18/2026 | PUT | $1,160.00 | 37 | -75 | -66.96% |
| 06/18/2026 | CALL | $1,160.00 | 650 | -92 | -12.40% |
| 06/18/2026 | CALL | $1,100.00 | 1,475 | -99 | -6.29% |
| 06/18/2026 | CALL | $1,200.00 | 2,676 | -158 | -5.58% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.74% | 26M | 11.45B |
| Vanguard 500 Index Fund | 1.92% | 18.23M | 8.03B |
| Vanguard/Primecap Fund | 1.56% | 14.85M | 6.54B |
| Fidelity 500 Index Fund | 0.91% | 8.65M | 3.81B |
| SPDR S&P 500 ETF Trust | 0.90% | 8.54M | 3.76B |
| Vanguard Specialized-Health Care Fund | 0.80% | 7.64M | 3.37B |
| iShares Core S&P 500 ETF | 0.74% | 7.04M | 3.1B |
| Washington Mutual Investors Fund | 0.73% | 6.95M | 3.06B |
| Growth Fund Of America Inc | 0.71% | 6.7M | 2.95B |
| Select Sector SPDR Fund-Health Care | 0.67% | 6.41M | 2.82B |
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own
06/19 04:30 am
The Motley Fool
Read more3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
06/18 11:41 am
Investing.com
Read more3 Under-the-Radar Stocks to Buy and Hold for a Decade
06/16 03:30 am
The Motley Fool
Read moreConfo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026
06/15 03:00 pm
GlobeNewswire Inc.
Read moreNovo Nordisk’s Wegovy Pill Turns Pricing Pain Into a Volume Bet
06/15 02:07 pm
Investing.com
Read moreEli Lilly Eyes Label Expansion For Leukemia Drug
06/15 01:43 pm
Benzinga
Read moreShould You Buy Eli Lilly Stock Now or Wait for a Dip?
06/15 12:30 pm
The Motley Fool
Read more3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
06/14 08:15 am
The Motley Fool
Read morePfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About
06/12 12:32 pm
The Motley Fool
Read moreAbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
06/12 06:15 am
The Motley Fool
Read moreIs Viking Therapeutics Stock Going to $100?
06/12 01:15 am
The Motley Fool
Read moreWhy 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%
06/10 01:27 pm
The Motley Fool
Read moreMetastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
06/10 01:00 pm
GlobeNewswire Inc.
Read moreWhy Eli Lilly Stock Climbed to a New All-Time High Today
06/08 09:13 pm
The Motley Fool
Read moreLilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?
06/08 05:23 pm
The Motley Fool
Read moreStock Market Today, June 8: Marvell, Intel, and Micron Lead Tech Stock Rebound
06/08 05:03 pm
The Motley Fool
Read moreAlcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight
06/08 01:00 pm
GlobeNewswire Inc.
Read moreA Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
06/08 12:14 pm
The Motley Fool
Read moreEli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages
06/08 10:03 am
Benzinga
Read moreNovo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs
06/08 08:55 am
Benzinga
Read morePfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
06/06 12:15 pm
The Motley Fool
Read moreNovo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
06/06 09:15 am
The Motley Fool
Read moreStock Market Today, June 4: Broadcom Drags on Nasdaq at Midday
06/04 12:39 pm
The Motley Fool
Read moreWeight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies
06/04 12:17 pm
Benzinga
Read moreEli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
06/04 09:27 am
The Motley Fool
Read morePrediction: Eli Lilly Will Be Worth More Than SpaceX in 2 Years
06/03 01:17 pm
The Motley Fool
Read more1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
06/03 12:05 pm
The Motley Fool
Read moreState Street's Health Care ETF Tops Invesco's on Yield and Returns
06/02 07:10 am
The Motley Fool
Read moreEli Lilly Deepens Innovation Push Through New Biopharma Collaborations
06/01 01:19 pm
Benzinga
Read moreLilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors
05/30 08:15 am
The Motley Fool
Read moreThe Smartest Growth Stocks to Buy With $2,000 Right Now
05/30 06:15 am
The Motley Fool
Read moreStock Market Today, May 28: Tech Stocks Rise as Snowflake Surges After $6 Billion Amazon Deal and Strong Earnings
05/28 02:06 pm
The Motley Fool
Read moreContrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
05/28 12:15 pm
The Motley Fool
Read moreVHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
05/28 08:07 am
The Motley Fool
Read moreTrogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
05/28 07:00 am
GlobeNewswire Inc.
Read more5 Undervalued Stocks You Can Buy and Hold Forever
05/28 04:15 am
The Motley Fool
Read morePresident Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
05/27 02:02 pm
The Motley Fool
Read moreGLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
05/27 11:17 am
The Motley Fool
Read moreTherini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
05/27 10:00 am
GlobeNewswire Inc.
Read moreMicron Just Became America's 10th-Most-Valuable Company. Wall Street Says It Could Pass Tesla and Meta Next.
05/26 10:16 pm
The Motley Fool
Read moreIs Eli Lilly Stock an Undervalued Stock to Buy?
05/26 06:17 pm
The Motley Fool
Read moreInvestment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing
05/26 02:29 pm
The Motley Fool
Read moreFrom Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave
05/26 01:38 pm
Benzinga
Read moreCurevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention
05/26 06:45 am
Benzinga
Read morePrediction: These 2 Obesity Drug Stocks Could Double in 2026
05/26 04:04 am
The Motley Fool
Read moreChamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62%
05/26 02:06 am
Benzinga
Read moreEli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro
05/25 07:15 pm
The Motley Fool
Read more